Insider Transactions in Q3 2024 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 30
2024
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
646
-12.71%
|
$323,000
$500.0 P/Share
|
|
Aug 30
2024
|
Sangeeta N. Bhatia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
646
+11.28%
|
$98,192
$152.74 P/Share
|
|
Aug 30
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,784
-27.46%
|
$1,888,216
$499.0 P/Share
|
|
Aug 08
2024
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
1,292
-22.56%
|
$602,072
$466.29 P/Share
|
|
Aug 08
2024
|
Sangeeta N. Bhatia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,292
+18.41%
|
$196,384
$152.74 P/Share
|
|
Aug 07
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-8.93%
|
$1,085,280
$476.75 P/Share
|
|
Aug 01
2024
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
5,295
-11.69%
|
$2,689,860
$508.0 P/Share
|
|
Aug 01
2024
|
Bruce I Sachs Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,295
+10.47%
|
$661,875
$125.71 P/Share
|
|
Jul 30
2024
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
15,202
-14.32%
|
$7,677,010
$505.0 P/Share
|
|
Jul 24
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-8.2%
|
$1,112,640
$488.46 P/Share
|
|
Jul 22
2024
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
15,202
-12.52%
|
$7,555,394
$497.0 P/Share
|
|
Jul 10
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-7.58%
|
$1,110,360
$487.34 P/Share
|